Equities research analysts expect Intrexon (NYSE:XON) to announce ($0.24) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Intrexon’s earnings, with estimates ranging from ($0.26) to ($0.22). Intrexon reported earnings of ($0.26) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 7.7%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Intrexon will report full-year earnings of ($0.92) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.47). For the next financial year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.75) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Intrexon.
Intrexon (NYSE:XON) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. The company had revenue of $77.03 million during the quarter, compared to analysts’ expectations of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business’s revenue for the quarter was up 67.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) EPS.
Shares of NYSE:XON traded up $0.06 during midday trading on Monday, hitting $18.00. The stock had a trading volume of 1,131,339 shares, compared to its average volume of 1,797,982. The stock has a market capitalization of $2,315.45, a PE ratio of -19.57 and a beta of 1.11. The company has a current ratio of 1.92, a quick ratio of 1.67 and a debt-to-equity ratio of 0.01. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.
A number of hedge funds have recently added to or reduced their stakes in XON. Bank of New York Mellon Corp increased its position in Intrexon by 1.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock worth $4,512,000 after purchasing an additional 3,234 shares in the last quarter. SG Americas Securities LLC acquired a new position in Intrexon during the 3rd quarter worth approximately $139,000. JPMorgan Chase & Co. increased its position in Intrexon by 7,504.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock worth $1,122,000 after purchasing an additional 58,838 shares in the last quarter. Wells Fargo & Company MN increased its position in Intrexon by 13.8% during the 3rd quarter. Wells Fargo & Company MN now owns 118,462 shares of the biotechnology company’s stock worth $2,252,000 after purchasing an additional 14,333 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Intrexon during the 3rd quarter worth approximately $1,945,000. Institutional investors and hedge funds own 75.95% of the company’s stock.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.